Evidence map›Paper›PMID 25975837›Full record

Trial reportHaematologica2015

ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2.

Saskia A G M Cillessen, Nathalie J Hijmering, Laura M Moesbergen, Wim Vos, Sue Ellen Verbrugge, Gerrit Jansen, Otto J Visser, Joost J Oudejans, Chris J L M Meijer

Open access · goldAbstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Saskia A G M CillessenDepartment of Clinical Pathology, VU University Medical Center, Amsterdam sagm.cillessen@vumc.nl.
Nathalie J HijmeringDepartment of Clinical Pathology, VU University Medical Center, Amsterdam.
Laura M MoesbergenDepartment of Clinical Pathology, VU University Medical Center, Amsterdam.
Wim VosDepartment of Clinical Pathology, VU University Medical Center, Amsterdam.
Sue Ellen VerbruggeDepartment of Rheumatology, VU University Medical Center, Amsterdam.
Gerrit JansenDepartment of Rheumatology, VU University Medical Center, Amsterdam.
Otto J VisserDepartment of Hematology, VU University Medical Center, Amsterdam.
Joost J OudejansDepartment of Clinical Pathology, VU University Medical Center, Amsterdam Department of Pathology, Diakonessenhuis, Utrecht, The Netherlands.
Chris J L M MeijerDepartment of Clinical Pathology, VU University Medical Center, Amsterdam.
Amsterdam UMC Location VUmc · NLUniversity Hospital and Clinics · USUniversity Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, Large-Cell, AnaplasticReceptor Protein-Tyrosine KinasesAnaplastic Lymphoma Kinasebcl-2-Associated X ProteinBortezomibFemaleGene Expression Regulation, NeoplasticHumansMaleProto-Oncogene Proteins c-bcl-2Tumor Cells, CulturedUp-RegulationALK protein, humanAnaplastic Lymphoma KinaseBAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanBortezomibPMAIP1 protein, humanProto-Oncogene Proteins c-bcl-2Receptor Protein-Tyrosine Kinasesanaplastic large cell lymphomaapoptosisBcl-2bortezomibchemotherapy-resistanceNoxa

Identifiers

PMID25975837
PMCPMC4800697
OpenAlexW1952247984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.